Navigation Links
Most breast cancer surgeons don't talk to patients about reconstruction options, U-M study finds
Date:12/20/2007

ANN ARBOR, Mich. Only a third of patients with breast cancer discussed breast reconstruction options with their surgeon before their initial surgery, according to a new study from the University of Michigan Comprehensive Cancer Center.

Whats more, women who did discuss reconstruction up front were four times more likely to have a mastectomy compared to those women who did not discuss reconstruction.

The surgical decision making for breast cancer is really centered on patient preference. Long-term outcomes are the same regardless of whether a woman is treated with a lumpectomy or a mastectomy. But that choice could have significant impact on a womans quality of life, sexuality and body image. Its important for women to understand all of their surgical options including breast reconstruction so they can make the best choice for themselves, says study author Amy Alderman, M.D., M.P.H., assistant professor of plastic surgery at the U-M Medical School.

The study appears Dec. 21 in the online version of the journal Cancer, and will appear in the Feb. 1 print edition.

The study looked at 1,178 women from the Detroit and Los Angeles metropolitan areas who had undergone surgery for breast cancer. Patients were contacted about three months after diagnosis and were asked whether they had discussed breast reconstruction with their surgeon before their surgery. Patients were also asked whether knowing about reconstruction options affected their decision to receive a mastectomy.

The researchers found that younger and more educated women were more likely to discuss reconstruction with their surgeon. They also found that this discussion significantly affected a womans treatment decision, with women who knew about reconstruction options four times more likely to choose a mastectomy.

Breast reconstruction can be performed immediately after a mastectomy, which removes the entire breast. This type of reconstruction leads to better aesthetic outcomes and psychological benefits for the patient, compared to delayed reconstruction, previous studies have shown.

To many women, breast reconstruction is a symbol of hope that they can get past this cancer diagnosis. Reconstruction is not necessarily the right option for every woman and not everyone is going to choose reconstruction, but I think its important that every woman is informed of what the benefits of reconstruction can be for their physical and emotional well being, Alderman says.

The researchers urge general surgeons to include discussion of all surgical options lumpectomy, mastectomy and mastectomy with reconstruction at a point when a patient is considering her choices. General surgeons could refer patients to plastic surgeons to discuss options before the initial surgery. Decision aids should also incorporate information about reconstruction, the researchers write.

Patients need to be educated consumers of their health care. If a physician does not bring up an option, the patient needs to ask. She needs to either ask the physician to provide the information or ask for a referral to a specialist who can provide the information. Women need to be proactive about their health care, Alderman says.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... has recently contributed a medical article to the newly revamped Cosmetic Town ... article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: